Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9748596 | 0.77 | — | — | |
| SCHEMBL24833 | 0.75 | — | — | |
| SCHEMBL2343048 | 0.75 | MEN1 (0.40) | ALDH1A1TSHRFGFR4 | |
| SCHEMBL11405605 | 0.74 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL8734005 | 0.74 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL9659491 | 0.74 | ALDH1A1 (0.36) | ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL8814151 | 0.73 | ALDH1A1 (0.33) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4378364 | 0.73 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL2063074 | 0.73 | — | — | |
| Hydrochloric Acid SCHEMBL2339828 | 0.73 | MEN1 (0.39) | ALDH1A1TSHRFGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291973-A1 | Novel Quinazoline Derivatives and Their Medical Use | NEUROSEARCH A/S (DK) | 2009-11-26 | — | — | US | claimed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291973-A1 | Novel Quinazoline Derivatives and Their Medical Use | KCNA7, KCNN3, KCNQ5 | ALDH1A1 3467/4885TSHR 3532/4885FGFR4 3587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.